New drug combo targets tough cancers in early trial

NCT ID NCT05431270

Recruiting now Disease control Sponsor: Phanes Therapeutics Source: ClinicalTrials.gov ↗

First seen May 19, 2026 · Last updated Jun 14, 2026 · Updated 8 times

Summary

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see if it helps shrink tumors. About 40 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Carolina BioOncology Institute
RECRUITING

Huntersville, North Carolina, 28078, United States
NEXT Oncology
RECRUITING

Fairfax, Virginia, 22031, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute University of Oklahoma
RECRUITING

Oklahoma City, Oklahoma, 73104, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Tranquility Research
TERMINATED

Webster, Texas, 77598, United States

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER PANCREATIC DUCTAL ADENOCARCINOMA